表皮水疱症(EB)の疫学予測(~2028)

◆英語タイトル:Epidermolysis Bullosa (EB)—Epidemiology Forecast—2028
◆商品コード:DATA00109031
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:81
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD3,250 ⇒換算¥364,000見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,750 ⇒換算¥1,092,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Epidermolysis Bullosa (EB)—Epidemiology Forecast—2028
DelveInsight’s ‘Epidermolysis Bullosa (EB)—Epidemiology Forecast—2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology trends of EB in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae. Epidermolysis bullosa usually is diagnosed in babies and children, but milder types can develop later in adulthood.

EB may be inherited in either a dominant or recessive form. In dominant EB, one parent usually carries the gene and is affected by the condition themselves, while the birth of a child suffering from the recessive form is usually totally unexpected since both parents can carry the EB gene without displaying the condition themselves. In dominant EB, there is a 50% chance of passing the disorder to children: in recessive EB the chance is 25%.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028
Epidermolysis Bullosa (EB)—Disease Understanding

Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma.

There are four major types of EB, depending on the location of the target proteins and level of the blisters: EB simplex (epidermolytic), junctional EB (lucidolytic), dystrophic EB (dermolytic), and Kindler syndrome (mixed levels of blistering). Apart from this when EB also occurs due to any defect in the immune system it is called epidermolysis bullosa acquisita (EBA).

Epidermolysis Bullosa (EB) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Epidermolysis Bullosa (EB) in the 7MM, Total Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in the 7MM, and Type-specific Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in the 7MM) scenario of Epidermolysis Bullosa (EB) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.

According to DelveInsight, the total diagnosed cases of Epidermolysis Bullosa (EB) were found out to be 39,433 in 2017, in the 7MM. The number of Epidermolysis Bullosa (EB) cases in the 7MM is expected to increase during the study period of 2017–2028.

In 2017, there were 26,104 prevalent cases of Epidermolysis Bullosa in the United States. Assessments as per DelveInsight’s analysts show that the total prevalent cases of Epidermolysis Bullosa are subjected to increase during the study period.

Among the European countries, the United Kingdom had the highest prevalent population of Epidermolysis Bullosa with 5,037 cases, followed by Germany which had a prevalent population of 4,919 in 2017. On the other hand, Spain had the lowest prevalent population of 928 in 2017.

Epidermolysis Bullosa is of several types, and three major types of Epidermolysis bullosa includes Epidermolysis bullosa simplex (EBS), junctional EB (JEB), and dystrophic EB (DEB). Assessments as per DelveInsight’s analysts show that the majority of cases of EB are Epidermolysis bullosa simplex in the United States, however the similar trend is not followed by other countries. In 2017, there were 18,599 cases of EBS, 1,240 cases of JEB, and 4,960 cases of DEB in the United States. DEB is further divided as recessive and dominant. Out of 4,960 cases of DEB in the United States in 2017, 2,358 cases were recessive DEB and 2,602 cases were dominant DEB.

Epidermolysis Bullosa (EB) Report Insights
• The report covers a descriptive overview of the Epidermolysis Bullosa (EB), explaining its causes, risk factors, pathophysiology, and diagnosis.
• Comprehensive insight has been provided into the epidemiology Epidermolysis Bullosa (EB) in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• Assesses growth opportunities in 7MM countries with respect to the patient population.

Epidermolysis Bullosa (EB) Report Key Strengths
• 10-Year Forecast
• 7MM Coverage
• Epidemiology Segmentation by Total diagnosed cases
• Type-specific diagnosed prevalent cases

Key Benefits
• Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by Severity

【レポートの目次】

1. Key Insights
2. Epidermolysis Bullosa (EB) Epidemiology Overview at a Glance
2.1. Patient Share (%) Distribution of Epidermolysis Bullosa (EB) in 2017
2.2. Patient Share (%) Distribution of Epidermolysis Bullosa (EB) in 2028
3. Epidermolysis Bullosa (EB): Disease Background and Overview
3.1. Introduction
3.2. Causes of Epidermolysis Bullosa
3.3. Signs and Symptoms of Epidermolysis Bullosa
3.4. Classification of Epidermolysis Bullosa
3.5. Pathophysiology of Epidermolysis Bullosa
3.6. Genetic Bases of Epidermolysis Bullosa
3.7. Diagnosis of Epidermolysis Bullosa
3.8. Diagnostic Guidelines
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of Epidermolysis Bullosa
4.3. 7MM Diagnosed Prevalent Patient Population of Epidermolysis Bullosa
4.4. 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa
5. Country Wise-Epidemiology of Epidermolysis Bullosa
5.1. United States Epidemiology
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Cases of Epidermolysis Bullosa in the United States
5.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United States
5.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.1.1. Assumptions and Rationale
5.2.1.2. Total Prevalent Cases of Epidermolysis Bullosa in Germany
5.2.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in Germany
5.2.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany
5.2.2. France
5.2.2.1. Assumptions and Rationale
5.2.2.2. Total Prevalent Cases of Epidermolysis Bullosa in France
5.2.2.3. Diagnosed Prevalence of Epidermolysis Bullosa in France
5.2.2.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in France
5.2.3. Italy
5.2.3.1. Assumptions and Rationale
5.2.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Italy
5.2.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Italy
5.2.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy
5.2.4. Spain
5.2.4.1. Assumptions and Rationale
5.2.4.2. Total Prevalent Cases of Epidermolysis Bullosa in Spain
5.2.4.3. Diagnosed Prevalence of Epidermolysis Bullosa in Spain
5.2.4.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain
5.2.5. United Kingdom
5.2.5.1. Assumptions and Rationale
5.2.5.2. Total Prevalent Cases of Epidermolysis Bullosa in the United Kingdom
5.2.5.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom
5.2.5.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom
5.3. Japan Epidemiology
5.3.1. Assumptions and Rationale
5.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Japan
5.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Japan
5.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan
6. Appendix
6.1. Report Methodology
7. DelveInsight Capabilities
8. Disclaimer
9. About DelveInsight
Table 1 Classification of Epidermolysis Bullosa (EB)
Table 2 Level of Evidence
Table 3 Grades of recommendation made by the guideline panel
Table 4 Level of Evidence
Table 5 Total Prevalent Patient Population of Epidermolysis Bullosa in 7MM (2017-2028)
Table 6 Diagnosed Prevalent Patient Population of Epidermolysis Bullosa in the 7MM (2017-2028)
Table 7 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa (2017-2028)
Table 8 Total Prevalent Population of Epidermolysis Bullosa in the United States (2017-2028)
Table 9 Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
Table 10 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
Table 11 Total Prevalent Population of Epidermolysis Bullosa in Germany (2017-2028)
Table 12 Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
Table 13 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
Table 14 Total Prevalent Population of Epidermolysis Bullosa in France (2017-2028)
Table 15 Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
Table 16 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
Table 17 Total Prevalent Population of Epidermolysis Bullosa in Italy (2017-2028)
Table 18 Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
Table 19 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
Table 20 Total Prevalent Population of Epidermolysis Bullosa in Spain (2017-2028)
Table 21 Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
Table 22 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
Table 23 Total Prevalent Population of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Table 24 Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Table 25 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Table 26 Total Prevalent Population of Epidermolysis Bullosa in Japan (2017-2028)
Table 27 Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
Table 28 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
Figure 1 Blister formation in Epidermolysis bullosa
Figure 2 Some common symptoms of Epidermolysis Bullosa
Figure 3 Types of Epidermolysis Bullosa
Figure 4 Keratin Proteins and EB Simplex
Figure 5 Pathology Outlines
Figure 6 The mechanism of epidermolysis bullosa
Figure 7 Pathogenesis of Epidermolysis Bullosa Acquisita
Figure 8 Total Prevalent Patient Population of Epidermolysis Bullosa in 7MM (2017-2028)
Figure 9 Diagnosed Prevalence of Epidermolysis Bullosa in the 7MM (2017-2028)
Figure 10 7MM Type Specific Diagnosed Prevalence of Epidermolysis Bullosa (2017-2028)
Figure 11 Total Prevalent Cases of Epidermolysis Bullosa in the United States (2017-2028)
Figure 12 Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
Figure 13 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
Figure 14 Total Prevalent Cases of Epidermolysis Bullosa in Germany (2017-2028)
Figure 15 Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
Figure 16 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
Figure 17 Total Prevalent Cases of Epidermolysis Bullosa in France (2017-2028)
Figure 18 Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
Figure 19 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
Figure 20 Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
Figure 21 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
Figure 22 Total Prevalent Cases of Epidermolysis Bullosa in Spain (2017-2028)
Figure 23 Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
Figure 24 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
Figure 25 Total Prevalent Cases of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Figure 26 Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Figure 27 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Figure 28 Total Prevalent Cases of Epidermolysis Bullosa in Japan (2017-2028)
Figure 29 Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
Figure 30 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[表皮水疱症(EB)の疫学予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆